Moreover, it is not clear to what degree IL28B genotype test results predict response to HCV PI + PEG-IFN/RBV therapy for particular subsets of patients, such as African Americans, HIV-coinfected or posttransplant patients, and those with cirrhosis. Here, IFNA1 is linked to Cirrhosis.